196 related articles for article (PubMed ID: 19923357)
21. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells.
Zagon IS; Verderame MF; McLaughlin PJ
Neuropeptides; 2003 Oct; 37(5):290-7. PubMed ID: 14607106
[TBL] [Abstract][Full Text] [Related]
22. Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
Goldenberg D; Zagon IS; Fedok F; Crist HS; McLaughlin PJ
Thyroid; 2008 Nov; 18(11):1165-70. PubMed ID: 19014324
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
McLaughlin PJ; Rogosnitzky M; Zagon IS
Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
[TBL] [Abstract][Full Text] [Related]
24. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
Qu N; Wang X; Meng Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
[TBL] [Abstract][Full Text] [Related]
25. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
26. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.
Cheng F; McLaughlin PJ; Banks WA; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R774-85. PubMed ID: 20592180
[TBL] [Abstract][Full Text] [Related]
27. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor.
Bisignani GJ; McLaughlin PJ; Ordille SD; Beltz MS; Jarowenko MV; Zagon IS
J Urol; 1999 Dec; 162(6):2186-91. PubMed ID: 10569617
[TBL] [Abstract][Full Text] [Related]
28. The biology of the opioid growth factor receptor (OGFr).
Zagon IS; Verderame MF; McLaughlin PJ
Brain Res Brain Res Rev; 2002 Feb; 38(3):351-76. PubMed ID: 11890982
[TBL] [Abstract][Full Text] [Related]
29. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
31. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
[TBL] [Abstract][Full Text] [Related]
32. Opioid growth factor and the treatment of human pancreatic cancer: a review.
Zagon IS; McLaughlin PJ
World J Gastroenterol; 2014 Mar; 20(9):2218-23. PubMed ID: 24605021
[TBL] [Abstract][Full Text] [Related]
33. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
34. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
35. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
36. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.
McLaughlin PJ; Levin RJ; Zagon IS
Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794
[TBL] [Abstract][Full Text] [Related]
37. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract][Full Text] [Related]
38. Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma.
Sikong Y; Wang Q; Cai M; Zhang A; Pang F; Cui X
Int J Clin Exp Pathol; 2019; 12(2):590-598. PubMed ID: 31933864
[TBL] [Abstract][Full Text] [Related]
39. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea.
Zagon IS; Ruth TB; Leure-duPree AE; Sassani JW; McLaughlin PJ
Brain Res; 2003 Mar; 967(1-2):37-47. PubMed ID: 12650964
[TBL] [Abstract][Full Text] [Related]
40. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stack BC; Levin RJ; Fedok F; Zagon IS
Cancer; 2003 Apr; 97(7):1701-10. PubMed ID: 12655527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
